-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly Agrees To Acquire Verve Therapeutics For $10.50/Share In Cash (An Aggregate Of Approximately $1B) Plus One Contingent Value Right Of Up To An Additional $3.00 Per Share, For A Total Potential Consideration Of Up To $13.50 Per Share (An Aggregate Of Up To Approximately $1.3B)

Benzinga·06/17/2025 10:47:53
Listen to the news
  • Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease
  • Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise